Investigator Versus Core Laboratory Evaluation of Coronary Flow and Related Mortality in the CULPRIT-SHOCK Trial.

Zeitouni M, Barthélémy O, Hauguel-Moreau M, Guedeney P, Rouanet S, Hage G, Overtchouk P, Brugier D, Vignolles N, Kerneis M, Silvain J, Collet JP, Vicaut E, Desch S, Zeymer U, Thiele H, Montalescot G.

Circ Cardiovasc Interv. 2019 Oct;12(10):e008296. doi: 10.1161/CIRCINTERVENTIONS.119.008296. Epub 2019 Oct 14. No abstract available.

En savoir +

Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.

Virone A, Bastard JP, Fellahi S, Capeau J, Rouanet S, Sibilia J, Ravaud P, Berenbaum F, Gottenberg JE, Sellam J.

RMD Open. 2019 Jul 21;5(2):e000897. doi: 10.1136/rmdopen-2019-000897. eCollection 2019.

En savoir +

Five-year mortality in patients with diabetic foot ulcer during 2009-2010 was lower than expected.

Amadou C, Carlier A, Amouyal C, Bourron O, Aubert C, Couture T, Fourniols E, Ha Van G, Rouanet S, Hartemann A.

Diabetes Metab. 2019 Aug 7. pii: S1262-3636(19)30123-5. doi: 10.1016/j.diabet.2019.04.010. [Epub ahead of print]

En savoir +

Insulin Pump Combined with Flash Glucose Monitoring: A Therapeutic Option to Improve Glycemic Control in Severely Nonadherent Patients with Type 1 Diabetes.

Halbron M, Bourron O, Andreelli F, Ciangura C, Jacqueminet S, Popelier M, Bosquet F, Rouanet S, Amouyal C, Hartemann A.

Diabetes Technol Ther. 2019 Jul;21(7):409-412. doi: 10.1089/dia.2019.0041.

En savoir +

High risk of heart failure associated with desmoglein-2 mutations compared to plakophilin-2 mutations in arrhythmogenic right ventricular cardiomyopathy/dysplasia.

Hermida A, Fressart V, Hidden-Lucet F, Donal E, Probst V, Deharo JC, Chevalier P, Klug D, Mansencal N, Delacretaz E, Cosnay P, Scanu P, Extramiana F, Keller DI, Rouanet S, Charron P, Gandjbakhch E.

Eur J Heart Fail. 2019 Feb 21. doi: 10.1002/ejhf.1423

En savoir +

External validation of risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers.

Thuillot M, Maupain C, Gandjbakhch E, Waintraub X, Hidden-Lucet F, Isnard R, Ader F, Rouanet S, Richard P, Charron P.

Eur J Heart Fail. 2019 Feb;21(2):253-254. doi: 10.1002/ejhf.1384. Epub 2019 Jan 9.

En savoir +

Long-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use: The FRANCE-TAVI registry.

Overtchouk P, Guedeney P, Rouanet S, Verhoye JP, Lefevre T, Van Belle E, Eltchaninoff H, Gilard M, Leprince P, Iung B, Barthelemy O, Le Breton H, Souteyrand G, Vicaut E, Montalescot G, Collet JP.

J Am Coll Cardiol. 2018 Aug 22.

En savoir +
Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection.

Henry J, Gottenberg JE, Rouanet S, Pavy S, Sellam J, Tubach F, Belkhir R, Mariette X, Seror R; Auto-Immunity and Rituximab investigators.

Rheumatology (Oxford). 2018 Mar 1

En savoir +
25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients.

Belle A, Gizard E, Conroy G, Lopez A, Bouvier-Alias M, Rouanet S, Peyrin-Biroulet L, Pawlotsky JM, Bronowicki JP.

United European Gastroenterol J. 2017 Feb

En savoir +
Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study.

Saraux A, Rouanet S, Flipo RM, Poncet JC, Fardellone P, Hilliquin P, Idier I, Cantagrel A.

Clin Exp Rheumatol. 2016 Mar-Apr

En savoir +
Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.

Gossec L, Steinberg G, Rouanet S, Combe B.

Clin Exp Rheumatol. 2015 Sep 7.

En savoir +

The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis.

Briot K, Rouanet S, Schaeverbeke T, Etchepare F, Gaudin P, Perdriger A, Vray M, Steinberg G, Roux C.

Joint Bone Spine. 2015 Mar;82(2):109-15. doi: 10.1016/j.jbspin.2014.10.015.

En savoir +

Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial.

Sellam J, Marion-Thore S, Dumont F, Jacques S, Garchon HJ, Rouanet S, Taoufik Y, Hendel-Chavez H, Sibilia J, Tebib J, …

Arthritis Rheumatol. 2014 Aug;66(8):2015-25. doi: 10.1002/art.38671.

En savoir +

CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.

Sellam J, Rouanet S, Hendel-Chavez H, Miceli-Richard C, Combe B, Sibilia J, Le Loët X, Tebib J, Jourdan R, Dougados M, Taoufik Y, Mariette X.

Arthritis Rheum. 2013 Sep;65(9):2253-61. doi: 10.1002/art.38023.

En savoir +

Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial.

Mariette X, Rouanet S, Sibilia J, Combe B, Le Loët X, Tebib J, Jourdan R, Dougados M.

Ann Rheum Dis. 2014 Aug;73(8):1508-14. doi: 10.1136/annrheumdis-2013-203480.

En savoir +

Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients.

Ruyssen-Witrand A, Rouanet S, Combe B, Dougados M, Le Loët X, Sibilia J, Tebib J, Mariette X, Constantin A.

Rheumatology (Oxford). 2013 Apr;52(4):636-41. doi: 10.1093/rheumatology/kes344.

En savoir +

Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study.

Dougados M, Nataf H, Steinberg G, Rouanet S, Falissard B.

Rheumatology (Oxford). 2013 Feb;52(2):391-9. doi: 10.1093/rheumatology/kes285.

En savoir +

Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial.

Chapurlat RD, Laroche M, Thomas T, Rouanet S, Delmas PD, de Vernejoul MC.

Osteoporos Int. 2013 Jan;24(1):311-20. doi: 10.1007/s00198-012-1947-4.

En savoir +

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.

Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM).

Eur J Haematol. 2012 Mar;88(3):249-59. doi: 10.1111/j.1600-0609.2011.01729.x.

En savoir +

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab.

Ruyssen-Witrand A, Rouanet S, Combe B, Dougados M, Le Loët X, Sibilia J, Tebib J, Mariette X, Constantin A.

Ann Rheum Dis. 2012 Jun;71(6):875-7. doi: 10.1136/annrheumdis-2011-200337.

En savoir +

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).

Bourlière M, Ouzan D, Rosenheim M, Doffoël M, Marcellin P, Pawlotsky JM, Salomon L, Fagnani F,Rouanet S, Pinta A, Vray M.

Antivir Ther. 2012;17(1):101-10. doi: 10.3851/IMP1935.

En savoir +

Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry.

Calès P, Zarski JP, Chapplain JM, Bertrais S, Sturm N, Michelet C, Babany G, Chaigneau J, Eddine Charaf M; multicentric groups (Fibrosys, ANRS HC 12, Fibrostop).

J Viral Hepat. 2012 Feb;19(2):e143-53. doi: 10.1111/j.1365-2893.2011.01531.x.

En savoir +

Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.

Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loët X, Combe B, Dougados M, Mariette X, Taoufik Y.

Arthritis Rheum. 2011 Dec;63(12):3692-701. doi: 10.1002/art.30599.

En savoir +

Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil.

Le Meur Y, Thierry A, Glowacki F, Rerolle JP, Garrigue V, Ouali N, Heng AE, Delahousse M, Albano L, Lang P, Couzi L, Jaureguy M, Lebranchu Y, Mousson C, Glotz D, Kessler M, Vrtovsnik F, Rouanet S, Tagieva N, Kamar N.

Transplantation. 2011 Dec 15;92(11):1244-51. doi: 10.1097/TP.0b013e318234e134.

En savoir +

Monitoring of bone turnover markers does not improve persistence with ibandronate treatment.

Roux C, Giraudeau B, Rouanet S, Dubourg G, Perrodeau E, Ravaud P.

Joint Bone Spine. 2012 Jul;79(4):389-92. doi: 10.1016/j.jbspin.2011.05.001.

En savoir +

High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).

Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM.

Gastroenterology. 2011 Jul;141(1):119-27. doi: 10.1053/j.gastro.2011.03.039.

En savoir +

B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.

Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loët X, Tebib J, Sibilia J, Taoufik Y, Dougados M, Mariette X.

Arthritis Rheum. 2011 Apr;63(4):933-8. doi: 10.1002/art.30233.

En savoir +

Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.

Zarski JP, Sturm N, Desmorat H, Melin P, Raabe JJ, Bonny C, Sogni P, Pinta A, Rouanet S, Babany G, Cheveau A, Chevallier M.

Liver Int. 2010 Aug;30(7):1049-58. doi: 10.1111/j.1478-3231.2010.02265.x.

En savoir +

Relation of high concentrations of plasma carboxy-terminal telopeptide of collagen type I with outcome in acute myocardial infarction.

Barthélémy O, Beygui F, Vicaut E, Rouanet S, Van Belle E, Baulac C, Degrandsart A, Dallongeville J, Montalescot G; OPERA Investigators.

Am J Cardiol. 2009 Oct 1;104(7):904-9. doi: 10.1016/j.amjcard.2009.05.029.

En savoir +

Aldosterone and long-term outcome after myocardial infarction: A substudy of the french nationwide Observatoire sur la Prise en charge hospitalière, l’Evolution à un an et les caractéristiques de patients présentant un infarctus du myocarde avec ou sans onde Q (OPERA) study.

Beygui F, Montalescot G, Vicaut E, Rouanet S, Van Belle E, Baulac C, Degrandsart A, Dallongeville J; OPERA Investigators.

Am Heart J. 2009 Apr;157(4):680-7. doi: 10.1016/j.ahj.2008.12.013.

En savoir +

A trial comparing local pain after subcutaneous injection of epoetin-beta versus darbepoetin-alpha in healthy volunteers.

Berthoux F, Ryckelynck JP, Rouanet S, Gelu-Mantoulet S, Montestruc F, Mouchel P, Choukroun G; Painless Investigators Coordinators.

Clin Nephrol. 2008 Jul;70(1):33-40.

En savoir +

STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry).

Montalescot G, Dallongeville J, Van Belle E, Rouanet S, Baulac C, Degrandsart A, Vicaut E; OPERA Investigators.

Eur Heart J. 2007 Jun;28(12):1409-17.

En savoir +

Topical ketoprofen patch in the treatment of tendinitis: a randomized, double blind, placebo controlled study.

Mazières B, Rouanet S, Guillon Y, Scarsi C, Reiner V.

J Rheumatol. 2005 Aug;32(8):1563-70.

En savoir +

Topical ketoprofen patch (100 mg) for the treatment of ankle sprain: a randomized, double-blind, placebo-controlled study.

Mazières B, Rouanet S, Velicy J, Scarsi C, Reiner V.

Am J Sports Med. 2005 Apr;33(4):515-23.

En savoir +